Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation

Volume: 13, Issue: 8, Pages: e145 - e147
Published: Aug 1, 2018
Abstract
Patients with ALK receptor tyrosine kinase gene (ALK)-rearranged NSCLC display exquisite sensitivity to ALK receptor tyrosine kinase inhibitors (TKIs). Unfortunately, resistance to treatment invariably occurs. Among the pharmacodynamic mechanisms of resistance, the emergence of the G1202R mutation represents a major concern for thoracic oncologists, as it predicts resistance to first-generation (crizotinib) and second-generation (ceritinib,...
Paper Details
Title
Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation
Published Date
Aug 1, 2018
Volume
13
Issue
8
Pages
e145 - e147
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.